DE3788899D1 - Intraläsionale Behandlung von Basalzellenkarzinoma mittels rekombinanten humanen alpha-Interferons. - Google Patents

Intraläsionale Behandlung von Basalzellenkarzinoma mittels rekombinanten humanen alpha-Interferons.

Info

Publication number
DE3788899D1
DE3788899D1 DE87304642T DE3788899T DE3788899D1 DE 3788899 D1 DE3788899 D1 DE 3788899D1 DE 87304642 T DE87304642 T DE 87304642T DE 3788899 T DE3788899 T DE 3788899T DE 3788899 D1 DE3788899 D1 DE 3788899D1
Authority
DE
Germany
Prior art keywords
cell carcinoma
recombinant human
basal cell
human alpha
alpha interferons
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE87304642T
Other languages
English (en)
Other versions
DE3788899T2 (de
Inventor
Daniel Jay Tanner
Edwin Arnold Peets
Kenneth Albert Smiles
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme Corp
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of DE3788899D1 publication Critical patent/DE3788899D1/de
Publication of DE3788899T2 publication Critical patent/DE3788899T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/21Interferons [IFN]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/21Interferons [IFN]
    • A61K38/212IFN-alpha
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DE87304642T 1986-05-27 1987-05-26 Intraläsionale Behandlung von Basalzellenkarzinoma mittels rekombinanten humanen alpha-Interferons. Expired - Fee Related DE3788899T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US86664486A 1986-05-27 1986-05-27

Publications (2)

Publication Number Publication Date
DE3788899D1 true DE3788899D1 (de) 1994-03-10
DE3788899T2 DE3788899T2 (de) 1994-05-05

Family

ID=25348060

Family Applications (1)

Application Number Title Priority Date Filing Date
DE87304642T Expired - Fee Related DE3788899T2 (de) 1986-05-27 1987-05-26 Intraläsionale Behandlung von Basalzellenkarzinoma mittels rekombinanten humanen alpha-Interferons.

Country Status (13)

Country Link
EP (1) EP0248583B1 (de)
JP (1) JPS62289526A (de)
KR (1) KR870010871A (de)
AT (1) ATE100717T1 (de)
AU (1) AU601741B2 (de)
CA (1) CA1295243C (de)
DE (1) DE3788899T2 (de)
DK (1) DK264787A (de)
ES (1) ES2061496T3 (de)
IE (1) IE62318B1 (de)
IL (1) IL82654A0 (de)
PH (1) PH26198A (de)
ZA (1) ZA873743B (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5028422A (en) * 1986-05-27 1991-07-02 Schering Corporation Treatment of basal cell carcinoma intralesionally with recombinant human alpha interferon
EP0278715A3 (de) * 1987-02-09 1989-03-08 Schering Corporation Verwendung von menschlichem Gamma-Interferon für die Behandlung von Basalzell-Karzinomen
EP0372809B1 (de) * 1988-12-01 1993-08-04 Schering Corporation Arzneimittel zur Intralesionsbehandlung von schuppenartigem Zellkarzinomen mit rekombinantem human-alpha-Interferon
US5256410A (en) * 1988-12-01 1993-10-26 Schering Corporation Treatment of squamous cell carcinoma intralesionally with recombinant human alpha interferon
IL100415A0 (en) * 1990-12-21 1992-09-06 Schering Corp Administering alpha interferon by oral inhalation to treat asthma and non-malignant proliferative pulmonary diseases
AU2018246292A1 (en) * 2017-03-31 2019-10-10 Accanis Biotech F&E Gmbh & Co Kg Prevention and treatment of non-melanoma skin cancer (NMSC)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3278234D1 (en) * 1981-10-13 1988-04-21 Exovir Inc Interferon-containing compositions and the use of these compositions in the treatment of herpetic infections, pre-malignant skin lesions, skin malignancies and psoriasis
AU1153083A (en) * 1982-01-15 1983-07-28 Cetus Corporation Interferon-alpha 54
EP0098864A1 (de) * 1982-01-15 1984-01-25 Cetus Corporation Interferon-alpha 74
US5098703A (en) * 1982-01-15 1992-03-24 Cetus Corporation Interferon-alpha 76
US4822605A (en) * 1986-02-18 1989-04-18 Exovir, Inc. Compositions and methods employing the same for the treatment of viral and cancerous skin lesions and the like
US4853218A (en) * 1987-02-24 1989-08-01 Schering Corporation Zinc-protamine-alpha interferon complex

Also Published As

Publication number Publication date
EP0248583B1 (de) 1994-01-26
IE62318B1 (en) 1995-01-25
AU7336687A (en) 1987-12-03
DK264787A (da) 1987-11-28
DE3788899T2 (de) 1994-05-05
EP0248583A3 (en) 1989-10-18
KR870010871A (ko) 1987-12-18
IE871358L (en) 1987-11-27
EP0248583A2 (de) 1987-12-09
IL82654A0 (en) 1987-11-30
CA1295243C (en) 1992-02-04
PH26198A (en) 1992-03-18
JPS62289526A (ja) 1987-12-16
ATE100717T1 (de) 1994-02-15
AU601741B2 (en) 1990-09-20
ES2061496T3 (es) 1994-12-16
ZA873743B (en) 1987-11-25
DK264787D0 (da) 1987-05-25

Similar Documents

Publication Publication Date Title
BG60253B1 (bg) Човешки тъканен плазминогенен активатор
IL87621A0 (en) Conjugates of cytokines with immunoglobulins,their preparation and pharmaceutical compositions containing them
IT1183181B (it) Derivati del 3-metil-imidazo(4,5-c)pirazolo con attivita' terapeutica e procedimento per la loropreparazione
DE3788899T2 (de) Intraläsionale Behandlung von Basalzellenkarzinoma mittels rekombinanten humanen alpha-Interferons.
ATE174798T1 (de) Die herstellung von zusammensetzungen zur behandlung von krankheiten der zellproliferation
ATE74272T1 (de) Pharmazeutischer stoff fuer die behandlung von myelogener leukaemie.
DK0643973T3 (da) Anvendelse af humant interferon-beta til fremstilling af farmaceutiske præparater til behandling af kronisk myeloid leukæmi
DE3773295D1 (de) Homogene rekombinante immun-interferon-fragmente und diese enthaltende pharmazeutische zusammensetzungen.
ES2115582T3 (es) Preparacion y aplicaciones de interferon-gamma.
DE68908119D1 (de) Arzneimittel zur intralesionsbehandlung von schuppenartigem zellkarzinomen mit rekombinantem human-alpha-interferon.
OA08768A (fr) Traitement du virus su SIDA par l'interféron alpha humain recombinant.
DE3750248T2 (de) Zubereitung und Behandlung der Haut mit Human-Leukocyten-Interferon.
DE69104619D1 (de) Verwendungsmethoden von humanem Gammainterferon 4-134.
ATE26267T1 (de) Pyrimidin-derivate, ausgestattet mit antiviraler wirkung.
KR920014480A (ko) 기흉 치료용 제약 조성물을 제조하기 위한 인간 인터류킨 2의 활성을 갖는 폴리펩티드의 용도
KR900012628A (ko) 감마 인터페론의 유효량을 함유하는 복강내 투여용 난소암 치료제

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee